PMBS - Puramed Bioscience, Inc. (OTCBB Stock)

[Aufan 1983]

Opened a starter position yesterday @ .77 and again @ .87 and WOW this really moves on air. This play is a SUPER LOW FLOAT and therefore a super low volume stock.

The good stuff:

The Outstanding share count is a tiny 11.986 million. The float is said to be roughly 2.6 million with insiders holding around 9 million shares.




SCHOFIELD, Wis.--(BUSINESS WIRE)--PuraMed Bioscience (OTC Bulletin Board: PMBS - News), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines targeting major consumer health needs including the treatment of migraine headaches, insomnia and tension-type headaches, under the brand name LipiGesic™, announced today that it has entered into a partnership with Avalanche Creative Services, Inc. to produce its first television commercial.
Based in New York City, Avalanche creates advertising and marketing that leads to marketplace movements. Avalanche has successfully created and produced over 100 direct response television commercials for nutritional supplement clients in the past six years that have collectively generated over $300 million worth of revenue. Well-known success stories include multiple projects for such companies as Iceland Health, Nutrition 21, Memo Prove, Avacor, Garden of Life, Scandanavian Clinical Nutrition, Cylapril, Fullbar, Focus Factor, Brazilian Basics and more. Avalanche is currently producing a 60- and 120-second spot for PuraMed that will feature the Company’s migraine product, LipiGesic™ M, with a completion date scheduled for early October 2009, at which point testing will begin. PuraMed seeks to air the commercial nationally.
“Through our partnership with Avalanche, we are creating a sustainable and memorable brand image for LipiGesic™ M that will showcase our non-prescription medication solution,” said PuraMed Bioscience CEO Russell Mitchell. “Our commercial will speak to viewers by showing them how our product fulfills a major need—affordable, readily available and effective relief for migraine headaches.
Mitchell continued, “We are pleased to work with Avalanche, and selected them because of their extensive experience in producing advertisements for companies that manufacture non-prescription drugs and supplements. We are confident that through our first direct-response commercial, we will effectively introduce our product to millions of consumers who will then recognize and seek out the LipiGesic™ brand name.”




About the company:

PuraMed BioScience

Puramed Bioscience, Inc. engages in the development and marketing of non-prescription medicinal and healthcare products. Its principal products include LipiGesic M, which provides acute relief from migraine headaches; and LipiGesic PM that provides remedy for insomnia and other sleep disorders. The company’s other products comprise LipiGesic H for common tension headaches; LipiGesic Smoker’s Pal, which provides relief from the symptoms associated with nicotine withdrawal; LipiGesic RLS for problematic leg cramps associated with Restless Leg Syndrome; LipiGesic GI that provides relief for symptoms associated with nighttime reflux disorders; and LipiGesic CS for canker sore outbreaks. Puramed Bioscience was founded in 2006 and is based in Schofield, Wisconsin. The Company began trading under the symbol “PMBS” in May 2008.

[Aufan 1983]

PMBS has launched into orbit

1.50 x 1.75 Run baby run!!!!!!!!!!!!!!!!!!

[Aufan 1983]

From another board but questions and answers was taken from the pmbs website.


When does PuraMed BioScience expect to launch its first commercial product and begin generating revenue?

PuraMed BioScience will launch its LipiGesic M migraine product via a direct-response infomercial scheduled for broadcast in October 2009.
********************************************

When do you anticipate generating revenue?

PuraMed BioScience expects to generate revenue in October 2009, which corresponds to the date the direct response commercial is scheduled to be televised.
******************************************

When do you expect to launch first product in retail or commercial environment?

PuraMed BioScience will approach retailers within 60-days from the initial airing of our LipiGesic M migraine product direct response television commercial.
*******************************************

Do PuraMed BioScience products require FDA approval

Unlike prescription drugs or medications, non-prescription healthcare remedies such as PuraMed products do not require FDA approval prior to entering the market. PuraMed products are nonetheless subject to substantial FDA and other federal regulations governing their use, labeling, advertising, manufacturing and ingredients. PuraMed BioScience believes that its current and proposed development, formulation, marketing and other practices and procedures will comply fully with all governmental regulations applicable to PuraMed products.
*******************************

How many products does PuraMed BioScience have in progress?

LipiGesic M for the relief of migraine headaches is the first PuraMed product that will be introduced to the market. Following its entrance into the market, two other products, LipiGesic PM for insomnia and LipiGesic H for tension headaches, will be developed and introduced. There are also product formulations for relief from canker sores, restless-leg syndrome, nighttime-reflux disorders, smoking cessation, and weight loss that will soon follow.

[Aufan 1983]

Nasty close... today took me from 1.00 to 1.99 and back to .99 and then back to 1.74 before closing right back @ 1.00. Bid and ask were both above the closing price.

[DollarChamp]

If you do your homework, you will clearly see that this stock will rise rapidly as soon as it gets noticed.

GLTA


Puramed (PMBS.OB)

Market Cap: 13,95 Mio$
Price: 1,05 $

Shares Out : 12,6 M ( 8,6 M Shares held by Insider)
Float : 2,6 Million



PuraMed Bioscience, Inc. (PMBS.OB) Targets Two Market Opportunities


PuraMed Bioscience, Inc., a non-prescription pharmaceutical company, believes it has identified huge and largely untapped market opportunities, and has laid out a solid plan to capture them. The company, based in Schofield, Wisconsin, was established with two specific goals in mind, representing these two OTC (over-the-counter) product opportunities.

The first objective is to rapidly build a substantial and profitable business based upon three OTC products already developed by the company founders. The products, designed for headache and insomnia relief, are each unique in their own class, and collectively target a $2 billion American market.

LipiGesic MTM is a proprietary formulation created for the acute relief of migraine headaches within minutes. LipiGesic HTM is designed to dramatically increase the speed and levels of relief of tension headaches, effective at low doses and with the fewest potential side effects. LipiGesic PMTM is a new class of OTC sleep aid containing a proprietary blend of ingredients for the quick and natural relief of insomnia.

The second, longer term objective is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a new kind of product line. By applying hard science to natural products, PuraMed believes it can deliver products providing better performance while having fewer side effects.

The company also believes their products will benefit from the kind of effective opportunity identification and marketing that is largely absent in the natural OTC market. Promising research in the field often goes overlooked for years by large pharmaceutical companies. Through the effective use of clinical trials in conjunction with carefully timed and aggressive marketing, PuraMed is convinced that it can better reach a major part of the OTC market.

The two founders of PuraMed, Russ Mitchell and Jim Higgins, both have extensive experience in the successful sale and distribution of new health products, with novel strategies that have proven highly effective over multiple applications. Through the use of outside production and other third party resources, they plan to rapidly build their position, and consider marketing to be key to the new company’s success.


About the Company

PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class .





Summary

Now is an exciting time for PMBS and its shareholders. To date it has kept a relatively low profile, choosing to focus on building value for itself by developing its technology and brands rather than market visibility. As the Company rolls out new products and expands the awareness of its existing brands, we believe investors will certainly notice the stock. As a result, the price and trading volume of PMBS should increase as investors learn about this incredible opportunity.

With a management team that has "done this before" to the tune of a $70 million company, we believe sales of products introduced by PMBS will be very strong. With wide profit margins on the products sold by PMBS, in our opinion, shareholders will benefit from a higher stock price as revenues and profits increase.

Growth oriented investors should consider adding shares of PMBS to their portfolio at these levels. Once its products show up on the shelves of major retailers and the stock begins to be more widely followed by Wall Street, investors could see five to ten-fold returns.

[DollarChamp]

Promising Product Pipeline...

LipiGesic™ M

LipiGesic™ M provides acute relief from migraine headaches, and contains the herbs feverfew and ginger as principal ingredients. PuraMed believes that its specific formulation of these herbs for its migraine remedy is unique and proprietary, providing relief from these severe headaches in minutes. The Company believes it will capture a material segment of the huge migraine headache remedy market. We believe that Americans spend in excess of $6 billion annually on headache pain relievers, and that over half of sufferers of migraine headaches rely exclusively on non-prescription medications.

We believe that at least 30 million Americans suffer from chronic migraine headaches with over 20 million of them having “severe” migraine conditions. Thus migraine headaches constitute a severe and disabling condition for millions of people. We further believe that the economic burden alone to the U.S. economy is in excess of $20 billion annually.

LipiGesic™ M is effective, available as a non-prescription remedy, without any known side effects, and affordable compared to more expensive migraine drugs based on prescription chemical formulations.


LipiGesic™ PM

LipiGesic™ PM is a new class of non-prescription sleep aid without any known side effects, and contains a proprietary blend of natural ingredients including Valerian, St. John’s Wort, and Chamomile. We believe that the proprietary blend of these ingredients provides an effective remedy for insomnia and other sleep disorders. The sleep aid market features products based primarily on chemical antihistamines.

Accordingly, the LipiGesic™ PM product provides a wide open market opportunity for an effective, natural alternative to prescription medications, which are somewhat addictive and often cause withdrawal symptoms and other side effects. We have priced LipiGesic™ PM as a premium sleep aid product, which provides us with a projected gross margin of approximately 80%. This large margin should leave us substantial room for ample introductory promotion, product allowances and other incentives conducive to achieving rapid market penetration.

Similar to the migraine remedy market, the market for sleep aid products represents a very large segment of the overall healthcare products marketplace. We believe that over half of all adults in the U.S. suffer from sleep disorders, and that many of them experience persistent insomnia. The National Center on Sleep Disorders has reported that there are as many as 70 million problem sleepers in the U.S. with many of them suffering from chronic sleep disorders. We believe that insomnia is second only to pain as a healthcare complaint.

Future LipiGesic™ Products

We have completed development of additional non-prescription products, which we intend to launch commercially over the next couple years after establishing a solid market for our initial two products. These other PuraMed products include:

LipiGesic™ H – provides relief for common tension headaches which afflict a majority of American adults from time to time. This remedy provides headache relief features a unique proprietary formulation of St. John’s Wort and common aspirin.

LipiGesic™ Smoker’s Pal – provides relief from the symptoms associated with nicotine withdrawal with the added benefit of an appetite suppressant.

LipiGesic™ RLS – provides relief of problematic leg cramps associated with Restless Leg Syndrome affecting a large segment of the population in the U.S.

LipiGesic™ GI – provides relief of symptoms associated with nighttime reflux disorders.

LipiGesic™ CS – provides fast relief for canker sore outbreaks.

[DollarChamp]

STILL FLYING UNDER RADAR !!




Puramed (PMBS.OB)

Market Cap: 13 Mio$
Price: 1 $

Shares Out : 12,6 M ( 8,6 M Shares held by Insider)
Float : 2,6 Million


Q: How many products does PuraMed BioScience have in progress?

A: LipiGesic M for the relief of migraine headaches is the first PuraMed product that will be introduced to the market. Following its entrance into the market, two other products, LipiGesic PM for insomnia and LipiGesic H for tension headaches, will be developed and introduced. There are also product formulations for relief from canker sores, restless-leg syndrome, nighttime-reflux disorders, smoking cessation, and weight loss that will soon follow.

Q: When do you anticipate generating revenue?

A: PuraMed BioScience expects to generate revenue in October 2009, which corresponds to the date the direct response commercial is scheduled to be televised.

Q: When do you expect to launch first product in retail or commercial environment?

A: PuraMed BioScience will approach retailers within 60-days from the initial airing of our LipiGesic M migraine product direct response television commercial.


Q: How big is the non-prescription market for migraines, insomnia and tension headaches?

A: Currently, the non-prescription market for headache pain and sleep is approximately $2.68 billion without Walmart and approximately $3.2 with Walmart.

[DollarChamp]

Bid & Ask up ..This stock will explode with more Volume !!!
http://www.otcmarkets.com/pink/quote...sp?symbol=pmbs

Realtime-Chart
http://ih.advfn.com/p.php?pid=static...p=0&t=19&vol=1

BUY ON BARCHART
http://www.barchart.com/quotes/PMBS

[DollarChamp]

Good news is coming very soon ..

http://www.otcstockreview.com/Files/...MBS_Review.pdf

Summary
Now is an exciting time for PMBS and its shareholders. To date it has kept a relatively low profile, choosing
to focus on building value for itself by developing its technology and brands rather than market visibility.
As the Company rolls out new products and expands the awareness of its existing brands, we believe
investors will certainly notice the stock. As a result, the price and trading volume of PMBS should
increase as investors learn about this incredible opportunity. With a management team that has "done
this before" to the tune of a $70 million company, we believe sales of products introduced by PMBS will
be very strong. With wide profit margins on the products sold by PMBS, in our opinion, shareholders will
benefit from a higher stock price as revenues and profits increase.
Growth oriented investors should consider adding shares of PMBS to their portfolio at these levels. Once
its products show up on the shelves of major retailers and the stock begins to be more widely followed
by Wall Street, investors could see five to ten-fold returns.

[DollarChamp]

New Link ...CHECK IT OUT
http://puramedbioscience.com/PuraMed...ile-4.2010.pdf